and came alongside confirmation of a rumoured takeover of Harpoon Therapeutics and its T-cell engager pipeline by MSD – now confirmed at $680 million – and a $425 million offer by Novartis for ...

Novartis has one of the industry’s largest R&D budgets - $9 billion in 2016 - with investors exerting continuous pressure on the company to prove the value of this investment.